Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.

@article{Aringer2012CurrentSO,
  title={Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.},
  author={Martin Aringer and Hans Ulrich Burkhardt and Gerd Reudiger Burmester and Rebecca Elise Fischer-Betz and Marlies Fleck and Wolfgang Graninger and Falk Hiepe and Annett Marita Jacobi and Ina K{\"o}tter and H. J. Lakomek and Helene M Lorenz and Bronwen Manger and Georg Schett and Reinhold Ernst Schmidt and Matthew Lee Schneider and Hendrik Schulze-Koops and Josef S Smolen and Christof Specker and Thomas Stoll and Anja Strangfeld and H. P. Tony and Peter Matthias Villiger and Rebecca Voll and Tania Witte and Thomas D{\"o}rner},
  journal={Lupus},
  year={2012},
  volume={21 4},
  pages={
          386-401
        }
}
Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening disease that often represents a therapeutic challenge because of its heterogeneous organ manifestations. Only glucocorticoids, chloroquine and hydroxychloroquine, azathioprine, cyclophosphamide and very recently belimumab have been approved for SLE therapy in Germany, Austria and Switzerland. Dependence on glucocorticoids and resistance to the approved therapeutic agents, as well as substantial toxicity, are… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Similar Papers

Loading similar papers…